Introduction
============

Heart rate variability (HRV) is a non-invasive method of measuring variations in heart rate, and it can be used to evaluate cardiovascular (CV) autonomic neuropathy and activities of the autonomic nervous system ([@B5]). In practice, HRV is defined as variations in instantaneous heart rate and R--R intervals measured using electrocardiography (ECG) ([@B5]). Abnormal HRV primarily reflects dysregulation between the sympathetic and parasympathetic nervous systems. Frequency-domain analysis of HRV has been increasingly used to assess the autonomic nervous system due to its non-invasiveness and availability.

A low HRV, indicating impaired autonomic function, has been reported in patients undergoing hemodialysis (HD), and it has been associated with adverse CV outcomes and even death in patients undergoing HD ([@B16]; [@B33]). Our recent study demonstrated that changes in HRV parameters before and after HD have a stronger predictive ability for overall and CV mortality than HRV parameters before HD ([@B8]). A previous study reported that HD patients with diabetes had a smaller degree of changes in HRV after HD than patients without diabetes, and that this may be related to diabetic autonomic neuropathy ([@B46]). However, the factors associated with changes in HRV in diabetic HD patients have yet to be clarified.

Many neurological diseases of in the elderly such as dementia ([@B17]), Parkinson's disease ([@B35]) and cognitive impairment ([@B28]) have been reported to be caused by age-related cholinergic dysfunction. In addition to neurological diseases, cholinergic degeneration has also been reported to play a role in an obstructed bladder ([@B38]) and constipation in the elderly, and especially in those with diabetes ([@B4]). The number of elderly patients undergoing HD has increased along with life expectancy, and these patients have been reported to be frailer ([@B15]) with greater functional and cognitive impairments compared to those who do not require HD ([@B2]). However, little is known about the association between age and autonomic regulation in HD patients with diabetes mellitus (DM). Therefore, the aims of this study were to investigate the relationship between age and HRV parameters before and after HD, and further investigate the factors associated with change in HRV in diabetic patients.

Materials and Methods {#s1}
=====================

Study Patients and Design
-------------------------

This study was conducted at a regional hospital in southern Taiwan, and included all maintenance HD patients except for those receiving HD at night. A total of 84 diabetic patients (45 males and 39 females) were enrolled from May 2012 to July 2012. All of these patients underwent HD three times per week, with each session lasting for 3.5--4.5 h, a blood flow rate of 250--300 mL/min, and a dialysate flow of 500 mL/min. *K*t/*V* was calculated from blood samples obtained before and after HD.

Ethics Statement
----------------

The study protocol was approved by the Institutional Review Board of Kaohsiung Medical University Hospital. Written informed consent was obtained from all of the enrolled patients, and the study was conducted according to the principles expressed in the Declaration of Helsinki. In addition, all of the patients consented to the inclusion and publication of their data in this study.

Electrocardiogram Signal Processing
-----------------------------------

Short-term power spectral analysis of HRV was performed in all of the enrolled patients in a quiet room with a temperature of 28°C. The HRV analysis was performed according to standard protocols as reported previously ([@B25]; [@B27]; [@B7]). Pericardial ECG was performed continuously for 5 min with the patients lying quietly in the supine position and breathing normally for at least 10 min. The ECG examinations were performed 30 min before and 30 min after HD during the day (8 a.m. to 5 p.m.), and the signals were recorded using an HRV analyzer (SS1C, Enjoy Research, Taipei, Taiwan) which was equipped with an analog-to-digital converter and a sampling rate of 256 Hz. The digitized ECG signals were acquired, stored, and processed using a computer. During analysis, each QRS complex was identified, and premature ventricular complexes and noise were removed using a standard QRS template using the software provided by the HRV analyzer. This was followed by resampling of the stationary *R*--*R* values with interpolation at 7.11 Hz to provide consistency over a time period ([@B25]).

HRV Frequency-Domain Analysis
-----------------------------

Frequency-domain analysis was conducted using fast Fourier transformation. The direct current component was first removed, and then the effect of leakage was reduced using a Hamming window ([@B24]). The power spectrum density was estimated based on FFT for each time segment (288 s; 2048 data points), and attenuation of the resulting power spectrum caused by sampling and the Hamming window was corrected. The power spectrum was then quantified into standard frequency-domain measurement including very low frequency (VLF) (0.003--0.04 Hz), high frequency (HF) (0.15--0.40 Hz), low frequency (LF) (0.04--0.15 Hz), total power (0.003--0.40 Hz) and LF/HF ratio HRV as previously reported ([@B5]). HF was normalized to the percentage of total power to detect the sympathetic influence on HRV as follows: HF% = HF/(total power-VLF)^∗^100%. All of the HRV parameters were logarithmically transformed to correct for skewness of the distribution ([@B5]).

Collection of Demographic, Medical, and Laboratory Data
-------------------------------------------------------

Demographic and medical data were obtained from medical records and patient interviews, and included age, sex and co-morbidities. An autoanalyzer (COBAS Integra 400, Roche Diagnostics GmbH, Mannheim, Germany) was used for all laboratory examinations which were conducted using fasting blood samples. The serum concentration of intact parathyroid hormone (iPTH) was measured using a commercially available two-sided immunoradiometric assay (CIS Bio International, Saclay, France). Ultrafiltration rate was defined as ultrafiltration divided by body weight. *K*t/*V* was used as a measure of dialysis efficiency, and was determined monthly using the Daugirdas method ([@B11]).

Statistical Analysis
--------------------

Statistical analysis was performed using SPSS for Windows version 15.0 (SPSS Inc. Chicago, IL, United States). HRV parameters are presented as percentage, mean ± standard deviation, and mean ± standard error of the mean. The duration of dialysis and levels of serum triglycerides and iPTH are presented as median (25th--75th percentile). Differences between groups were analyzed using the chi-square test for categorical variables and the independent *t*-test for continuous variables with an approximately normal distribution, or the Mann--Whitney *U* test for continuous variables with a skewed distribution. The Wilcoxon signed-rank test using non-parametric statistical analysis was carried out for comparisons of the HRV parameters before and after HD. Furthermore, two-ways repeated measures analysis of variance was used to test the interaction between age and change of HRV parameters after HD. Changes in the HRV (ΔHRV) parameters were calculated as those measured after HD minus those measured before HD. Multiple stepwise linear regression analysis was used to identify the factors associated with ΔHRV parameters. A *p*-value of less than 0.05 was considered to indicate a significant difference.

Results
=======

The mean age of the 84 enrolled patients with DM undergoing maintenance HD was 62.6 ± 10.1 years. Of these patients, 53.6% patients were male and 41.7% were ≥65 years old. Comparisons of the baseline characteristics between the patients aged \<65 years and ≥65 years are shown in **Table [1](#T1){ref-type="table"}**. Compared to the patients younger than 65 years, those ≥65 years of age were more predominantly female, and had lower systolic and diastolic blood pressures, lower total cholesterol, lower low-density lipoprotein (LDL) cholesterol and lower creatinine. Among all of the pre-dialysis HRV parameters, only HF% was significantly higher in the patients ≥65 years of age compared to those \<65 years.

###### 

Comparison of baseline characteristics between diabetes mellitus (DM) patients with age \<65 and ≥65 years old.

  Characteristics                                 All patients (*N* = 84)   Age \<65 years (*N* = 49)   Age ≥65 years (*N* = 35)   *p*
  ----------------------------------------------- ------------------------- --------------------------- -------------------------- ---------
  Age (year)                                      62.6 ± 10.1               56.2 ± 7.1                  71.5 ± 6.1                 \<0.001
  Male gender (%)                                 53.6                      63.3                        40.0                       0.035
  Duration of dialysis (year)                     3.3 (1.3--6.7)            2.9 (1.0--5.3)              5.2 (1.7--9.1)             0.082
  Smoking history (%)                             27.4                      32.7                        20.0                       0.200
  Hypertension (%)                                77.4                      81.6                        71.4                       0.270
  Coronary artery disease (%)                     38.1                      34.7                        42.9                       0.448
  Cerebrovascular disease (%)                     31.0                      28.6                        34.3                       0.576
  Systolic blood pressure (mmHg)                  164.0 ± 26.0              169.6 ± 24.5                155.6 ± 26.2               0.017
  Diastolic blood pressure (mmHg)                 84.1 ± 14.8               87.8 ± 13.9                 78.6 ± 14.6                0.006
  Laboratory parameters                                                                                                            
      Albumin (g/dL)                              3.8 ± 0.3                 3.8 ± 0.3                   3.7 ± 0.3                  0.051
      Fasting glucose (mg/dL)                     144.0 ± 62.8              133.4 ± 47.2                158.0 ± 77.3               0.102
      Triglycerides (mg/dL)                       152.5 (104--228.5)        177 (104.8--240.8)          132.5 (94.5--177.8)        0.156
      Total cholesterol (mg/dL)                   175.4 ± 44.2              188.1 ± 40.7                157.5 ± 43.2               0.002
      Hemoglobin (g/dL)                           10.3 ± 1.2                10.5 ± 1.0                  10.1 ± 1.5                 0.143
      Creatinine (mg/dL)                          9.3 ± 1.9                 9.8 ± 1.6                   8.5 ± 2.0                  0.002
      Potassium (mEq/L)                           4.5 ± 0.7                 4.5 ± 0.6                   4.4 ± 0.7                  0.499
      Total calcium (mg/dL)                       9.2 ± 1.0                 9.3 ± 0.9                   9.1 ± 1.0                  0.439
      Phosphorous (mg/dL)                         4.6 ± 1.1                 4.6 ± 1.1                   4.5 ± 1.1                  0.634
      Calcium-phosphorous product (mg^2^/dL^2^)   41.8 ± 11.5               42.8 ± 11.6                 40.4 ± 11.4                0.359
      iPTH (pg/mL)                                327.8 (183.8--463.3)      359.8 (193.0--498.7)        306.5 (177.9--364.9)       0.525
      Uric acid (mg/dL)                           7.6 ± 1.9                 7.8 ± 1.8                   7.3 ± 2.0                  0.227
      Kt/V (Daugirdes)                            1.5 ± 0.3                 1.5 ± 0.2                   1.6 ± 0.4                  0.653
      Ultrafiltration rate (%)                    4.4 ± 1.4                 4.3 ± 1.3                   4.6 ± 1.6                  0.415
  Pre-dialysis HRV parameters                                                                                                      
      VLF (ln ms^2^)                              3.59 ± 0.20               3.38 ± 0.21                 3.89 ± 0.38                0.215
      LF (ln ms^2^)                               1.39 ± 0.48               0.73 ± 0.77                 2.32 ± 0.38                0.104
      HF (ln ms^2^)                               1.60 ± 0.54               0.80 ± 0.88                 2.72 ± 0.38                0.082
      HF% (nu)                                    35.5 ± 1.7                32.5 ± 2.1                  39.8 ± 2.6                 0.032
      LF/HF ratio                                 --0.21 ± 0.14             --0.07 ± 0.19               --0.40 ± 0.19              0.243
  Post-dialysis HRV parameters                                                                                                     
      VLF (ln ms^2^)                              4.19 ± 0.19               4.01 ± 0.24                 4.45 ± 0.29                0.259
      LF (ln ms^2^)                               2.28 ± 0.50               2.02 ± 0.61                 2.64 ± 0.86                0.553
      HF (ln ms^2^)                               2.05 ± 0.55               1.86 ± 0.67                 2.31 ± 0.95                0.696
      HF% (nu)                                    29.6 ± 1.4                30.4 ± 1.8                  28.4 ± 2.4                 0.516
      LF/HF ratio                                 0.23 ± 0.13               0.16 ± 0.16                 0.34 ± 0.22                0.508
  Medications                                                                                                                      
      ACEI and/or ARB use                         28.6                      28.2                        29.2                       0.935
      Beta-blocker use                            30.2                      25.6                        37.5                       0.319
      Calcium channel blocker use                 31.7                      28.2                        37.5                       0.441

LDL, low-density lipoprotein; iPTH, intact parathyroid hormone; HRV, heart rate variability; LF, low frequency; HF, high frequency; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

Changes in HRV Parameters before and after HD
---------------------------------------------

In the patients aged \<65 years, VLF (*p* = 0.014), LF (*p* \< 0.001), and HF (*p* = 0.030), were significantly increased after HD. In comparison, LF (*p* = 0.043) was significantly increased in the patients ≥65 years of age, but HF% (*p* \< 0.007) was significantly decreased after HD (**Table [2](#T2){ref-type="table"}**). Two-ways repeated measures analysis of variance was carried out to elucidate the interaction between age and change of HRV parameters after HD. Of note, the interaction between age and change of HF% was significant (*p* = 0.023). There was no significant interaction between age and change of VLF (*p* = 0.852), LF (*p* = 0.316), HF (*p* = 0.189), and LF/HF ratio (*p* = 0.117).

###### 

Heart rate variability (HRV) parameters of DM patients with age \<65 and ≥65 years old before and after hemodialysis.

  HRV parameters (frequency domain)   Age \<65 years          Age ≥65 years                                                                 
  ----------------------------------- ----------------------- --------------------- --------- ----------------------- --------------------- -------
  VLF (ln ms^2^)                      3.75 (2.78--4.23)       4.03 (2.96--5.43)     0.014     4.21 (2.89--4.77)       4.34 (3.33--5.54)     0.176
  LF (ln ms^2^)                       1.52 (0.69--2.44)       2.34 (1.41--3.81)     \<0.001   2.55 (1.36--3.26)       3.43 (1.53--4.63)     0.043
  HF (ln ms^2^)                       1.89 (0.94--2.78)       2.31 (1.50--3.11)     0.030     2.98 (1.88--3.85)       2.53 (1.74--3.90)     0.905
  HF% (nu)                            31.2 (20.1--43.1)       29.8 (22.2--37.8)     0.885     39.5 (29.4--51.0)       28.5 (18.1--39.0)     0.007
  LF/HF ratio                         --0.19 (--1.11--0.77)   0.11 (--0.36--0.91)   0.665     --0.14 (--0.98--0.48)   0.25 (--0.52--1.17)   0.091

LDL, low-density lipoprotein; iPTH, intact parathyroid hormone; HRV, heart rate variability; LF, low frequency; HF, high frequency; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

Determinants of ΔHRV Parameters in the Patients \<65 Years Old
--------------------------------------------------------------

**Table [3](#T3){ref-type="table"}** shows the unstandardized β coefficients of ΔVLF, ΔLF, and ΔHF which were significant in **Table [2](#T2){ref-type="table"}** in the patients \<65 years old, after adjusting for age, sex, duration of HD, a history of smoking, hypertension, coronary artery disease and cerebrovascular disease, systolic and diastolic blood pressure, albumin, fasting glucose, triglycerides, total cholesterol, LDL-cholesterol, hemoglobin, creatinine, potassium, total calcium, phosphorous, calcium-phosphorous product, iPTH, uric acid, *K*t/*V*, ultrafiltration rate and medication. In the multivariate stepwise analysis, cerebrovascular disease (β = -1.160, *p* = 0.015), diastolic blood pressure (β = -0.018, *p* = 0.017), fasting glucose (β = -0.016, *p* = 0.001), hemoglobin (β = -0.897, *p* = 0.001), and beta-blocker use (β = 1.103, *p* = 0.009) were independently associated with ΔVLF. Diastolic blood pressure (β = -0.029, *p* = 0.030), and ultrafiltration rate (β = -0.272, *p* = 0.033) were associated with ΔLF. Cerebrovascular disease (β = -0.765, *p* = 0.049) was associated with ΔHF.

###### 

Determinants of ΔHRV parameters of DM patients with age \<65 years old.

  ΔHRV parameters                             Multivariate (stepwise)      
  ------------------------------------------- ---------------------------- -------
  ΔVLF                                                                     
      Cerebrovascular disease                 --1.160 (-2.074, --0.245)    0.015
      Diastolic blood pressure (per 1 mmHg)   --0.018 (--0.032, --0.003)   0.017
      Fasting glucose (per 1 mg/dL)           --0.016 (--0.025, --0.007)   0.001
      Hemoglobin (per 1 g/dL)                 --0.897 (--1.407, --0.387)   0.001
      Beta-blocker use                        1.103 (0.299, 1.906)         0.009
  ΔLF                                                                      
      Diastolic blood pressure (per 1 mmHg)   --0.029 (--0.003, --0.054)   0.030
      Ultrafiltration rate (per 1 %)          --0.272 (--0.024, --0.520)   0.033
  ΔHF                                                                      
      Cerebrovascular disease                 --0.765 (--1.527, --0.003)   0.049

Values expressed as unstandardized coefficient β and 95% confidence interval (CI). Covariates in the multivariate model included age, sex, duration of dialysis, a history of smoking, hypertension, coronary artery disease and cerebrovascular disease, systolic and diastolic blood pressure, albumin, fasting glucose, triglycerides, total cholesterol, LDL-cholesterol, hemoglobin, creatinine, potassium, total calcium, phosphorous, calcium-phosphorous product, iPTH, uric acid, Kt/V, ultrafiltration rate, and medications use including ACEI and/or ARB, Beta-blocker and calcium channel blocker.

Determinants of ΔHRV Parameters in the Patients ≥65 Years Old
-------------------------------------------------------------

**Table [4](#T4){ref-type="table"}** presents the unstandardized β coefficients of ΔLF and ΔHF% which were significant in **Table [2](#T2){ref-type="table"}** in the patients ≥65 years old after adjusting for demographic, clinical and biochemical characteristics and medications. In the multivariate stepwise analysis, systolic blood pressure (β = 0.060, *p* = 0.023), total cholesterol (β = -0.146, *p* \< 0.001) and hemoglobin (β = 1.466, *p* \< 0.001) were associated with ΔLF. Furthermore, cerebrovascular disease (β = 12.762, *p* = 0.047), systolic blood pressure (β = 0.357, *p* = 0.012), and fasting glucose (β = -0.126, *p* = 0.003) were associated with ΔHF%.

###### 

Determinants of ΔHRV parameters of DM patients with age ≥65 years old.

  ΔHRV parameters                            Multivariate (stepwise)      
  ------------------------------------------ ---------------------------- ---------
  ΔLF                                                                     
      Systolic blood pressure (per 1 mmHg)   0.060 (0.009, 0.111)         0.023
      Total cholesterol (per 1 mg/dL)        --0.146 (--0.173, --1.119)   \<0.001
      Hemoglobin (per 1 g/dL)                1.466 (0.822, 2.109)         \<0.001
  ΔHF %                                                                   
      Cerebrovascular disease                12.762 (0.216, 25.309)       0.047
      Systolic blood pressure (per 1 mmHg)   0.357 (0.090, 0.625)         0.012
      Fasting glucose (per 1 mg/dL)          --0.126 (--0.204, --0.048)   0.003

Covariates in the multivariate model included age, sex, duration of dialysis, a history of smoking, hypertension, coronary artery disease and cerebrovascular disease, systolic and diastolic blood pressure, albumin, fasting glucose, triglycerides, total cholesterol, LDL-cholesterol, hemoglobin, creatinine, potassium, total calcium, phosphorous, calcium-phosphorous product, iPTH, uric acid, Kt/V, ultrafiltration rate, and medications use including ACEI and/or ARB, Beta-blocker and calcium channel blocker.

Discussion
==========

In the present study, we investigated the relationship between age and ΔHRV in diabetic HD patients. We found that pre-dialytic HF% was significantly higher in the patients ≥65 years old than in those \<65 years old. In addition, the patients \<65 years old had increases in VLF, LF, and HF after HD, whereas the patients ≥65 years old had an increase in LF and a decrease in HF% after HD. Diastolic blood pressure, cerebrovascular disease, fasting glucose, hemoglobin, beta-blocker use and ultrafiltration rate were significantly associated with ΔHRV in the patients \<65 years old; whereas cerebrovascular disease, systolic blood pressure, fasting glucose, total cholesterol and hemoglobin were associated with ΔHRV in the patients ≥65 years old.

An increasing number of studies have investigated the effects of HD on the elderly ([@B2]). The first major finding of the current study is that VLF, LF, and HF increased significantly after HD in the patients aged \<65 years, whereas LF increased during HD but HF% decreased significantly in the patients ≥65 years old. HF has been reported to represent respiratory sinus arrhythmia and vagal control of heart rate ([@B14]). The function of autonomic nerve system of the elderly population might decline ([@B6]). [@B41] reported a decrease in parasympathetic nervous activity during the nighttime postoperatively in elderly patients, and concluded that this may be due to higher sympathetic nervous activity resulting in a decrease in parasympathetic nervous activity. In addition, [@B18] reported an increase in LF and a decrease in HF after HD, which is consistent with our findings and suggests impaired changes in the compensatory baroreflex-mediated activation of the sympathetic nervous system in elderly patients. Compared to pre-dialytic HRV, the changes of HRV during HD have been recognized as a stronger predictor of death, and impaired increase in HRV after HD was associated with mortality in HD patients ([@B8]). In our study, HRV increased significantly after HD in the patients aged \<65 years, but HF% was drastically decreased after HD in patients aged ≥65 years. This finding implies that impaired parasympathetic response to HD may be partly responsible for unfavorable outcomes in the elderly HD patients. Therefore, the present study appears that patients ≥65 years old with DM had worse autonomic nervous system function after HD than patients \<65 years old.

The current study also revealed that only pre-dialytic HF% was significantly higher in the patients ≥65 years old. Although HRV might be reduced with age, however, some studies showed the lack of negative correlation between age and HRV. [@B20] found that HRV was not negatively correlated with age in diabetic patients. Furthermore, [@B1] showed no correlation between age and HRV in diabetic group among patients with sleep apnea syndrome. [@B30] even found that HF significantly increased with age in elderly people aged between 60 and 86 years, these findings are similar to the work by [@B36] who were the first to examine HRV in the very elderly (age range 40--102 years). They demonstrated that while global 24-h HRV decreased with increasing age, HRV measures caused by parasympathetic modulation, such as pre-dialytic HF or HF%, did not decline with age. The real cause remains to be studied in diabetic maintenance HD patients.

In the present study, ultrafiltration rate was associated with changes in LF after HD in the patients \<65 years old. The process of ultrafiltration during HD reduces circulating volume and arterial pressure, which can be detected by baroreceptors to trigger a cardiac sympathetic response. [@B3] investigated autonomic nervous system changes during HD, and reported that the LF component of HRV increased during non-hypotensive dialysis. Furthermore, systolic and diastolic blood pressures were associated with ΔHRV in our diabetic patients undergoing HD. Dysregulation of the autonomic nervous system can lead to sustained hypertension, and subsequently to an increased risk of vascular complications ([@B34]; [@B26]). Hypertension has also been associated with lower HRV ([@B37]), which suggests that compromised sympathetic-vagal balance in patients with hypertension. In addition, fluid status may also play a role in the association between blood pressure and changes in HRV. [@B13] evaluated the effect of central volume on changes in the LF parameter of HRV in patients undergoing HD, and found that patients with a low hydration status before HD had an increased LF after HD, whereas those with a high hydration status before HD exhibited no significant change in LF. A lower central volume caused by dialysis can lead to alterations in the capacity of the CV system and thereby changes in LF In patients with a low hydration status. However, removal of the same volume of fluid during HD may not reduce the central volume sufficiently to reactivate oscillations in frequency in patients with a high hydration status, and this may explain the associations between blood pressure, ultrafiltration rate and ΔHRV in this study.

An increasing number of studies have reported an association between an imbalance of the autonomic nervous system and pathophysiological conditions, including, dyslipidemia, sudden death, coronary artery disease, heart failure, and CV risk factors. In the present study, total cholesterol was associated with reduction in LF after HD in the patients aged ≥65 years old. A low HRV has been reported to able to predict intima media thickness ([@B12]) and progression of coronary atherosclerosis ([@B19]) in patients with recent CV disorders. [@B29] investigated whether hypercholesterolemic atherosclerosis leads to impairment of the vagus nerve and worsening of HRV ([@B29]), and found that an increase in plaque size and substantial arterial remodeling led to outward stretching of the vessel wall behind the plaque, and was associated with autonomic dysfunction due to impaired vagal tone. This may explain the positive association between total cholesterol and reduction in HRV after HD in patients with diabetes.

Hemoglobin level was positively correlated with change in LF after HD in patients ≥65 years old in the present study. In line with our findings, a positive correlation between hemoglobin and LF was shown in HD patients ([@B32]). This implied that better sympathetic compensation occur as a result of fluid removal during HD in patients with better hemoglobin level. Anemia might be related higher non-transferrin-bound iron and labile plasma iron levels, leading to oxidative stress-mediated cardiac autonomic dysfunction, thus resulting in reduced HRV ([@B45]).

A lower HRV has been reported in patients with hemorrhagic and ischemic stroke ([@B23]; [@B10]), and baroreflex impairment has also been reported in these patients ([@B40]). In the current study, a history of cerebrovascular disease was associated with both decrease in VLF and HF after HD in the patients aged \<65 years old, and decrease in HF% after HD in the patients aged ≥65 years old. In other words, cerebrovascular disease was associated with a smaller degree in the decrease in HF% after HD. This implies that autonomic CV dysregulation and impaired parasympathetic reaction occur as a result of fluid removal during HD in patients with stroke.

Another finding of the current study is that fasting glucose was associated with a change in HRV in the diabetic patients. [@B46] investigated the effect of DM on blunted autonomic response in patients undergoing HD, this suggests that impaired autonomic function may be associated with damage caused by diabetes in autonomic neuropathy. In the current study, we also found an association between a high level of fasting glucose and a smaller degree of change in HF% after HD, implying that patients with diabetes and a high level of fasting glucose may have an impaired sympathy-vagal equilibrium. Microangiopathy has also been reported to play an important role in the development of diabetic neuropathy ([@B43], [@B42]). The advanced glycation end products interacts with their receptors, can have a biological effect on tissues resulting in the complications of diabetes, further contributing to endoneural vascular dysfunction, consequently peripheral nerve microangiopathy ([@B44]) and peripheral neuropathy ([@B39]).

There are several limitations to the present study. First, HRV can be measured in frequency or time domain parameters; however, we only used the frequency domain HRV. Although frequency domain parameters have been reported to be well correlated (*r* = 0.85) with time domain parameters, several time domain parameters have been reported to be clinically relevant ([@B22], [@B21]). Thus, time domain measurements need to be included in future studies. Second, spectral HRV measurements and their physiological interpretation are not clear as previously thought, and they also have many limitations. More recent measures of HRV (e.g., fractal/complexity/scale invariant measures, entropy-based measures) should also be investigated as spectral HRV measurements in future studies. Third, causal relationships in this cross-sectional study could not be confirmed, and future prospective studies are needed to address this issue. Fourth, the number of enrolled patients was relatively small, which may have limited the statistical power. The percentage of non-stationary segments was lacking. Finally, the circadian pattern of autonomic modulation of the heart rate has been reported to exhibit a reduced HRV during the day with increased sympathetic activity and increased HRV during the night with the predominance of vagal modulation ([@B31]; [@B9]). In the present study, in order to minimize the influence of the circadian rhythm, we performed all HRV examinations during the day (between 8 a.m. and 5 p.m.), however, the rhythm may have been lost in some patients and the influence could not be defined. A longer period of ECG recordings may have established a baseline for each patient.

Conclusion
==========

Our results demonstrated significant changes in HRV after HD in diabetic patients. In the patients aged ≥65 years, LF was increased, whereas HF% was decreased significantly after HD. Among the HRV parameters, age had an interaction with the change of HF%, suggesting impaired parasympathetic response to HD in the elderly patients. Moreover, systolic blood pressure, total cholesterol, hemoglobin, and hemoglobin were associated with ΔLF, whereas cerebrovascular disease, systolic blood pressure, and fasting glucose were associated with ΔHF% in patients aged ≥65 years. Further prospective studies and follow-up are needed to validate the effects of aging and HRV on the outcomes of patients with diabetes.
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